

Amendments to the Specification:

1) After the Title on page 1 of the specification, please add the following:

Cross-Reference to Related Applications

This application is a national stage application filed under 35 U.S.C. § 371 and claim priority to and benefit of a prior international application number PCT/GB00/01030, Antibodies Specific for CYP1B1, by William Melvin, et al., filed March 20, 2000, which claims priority to United Kingdom application 9906380.2, filed March 19, 1999. The full disclosure of the prior applications are incorporated herein by reference.

2) On page 3 of the original specification, please replace the second paragraph with the following:

Accordingly, in a first aspect, the present invention provides a method of making an antibody that specifically binds to cytochrome P450 CYP1B1, the method comprising raising the antibody using a peptide consisting of an amino acid sequence VNQWSVNHDPVKWPN (SEQ ID NO. 1) or PExFDPARFLDKDGy, where x is D or N and y is L or F (SEQ ID NOs. 2 to 5), or an antigenic fragment thereof.

3) On page 4 of the original specification, please replace the first full paragraph with the following:

In a further aspect, the present invention provides an antibody which is capable of specifically binding to cytochrome P450 CYP1B1, wherein the antibody recognises an epitope in the cytochrome P450 CYP1B1 protein included within the amino acid sequence VNQWSVNHDPVKWPN (SEQ ID NO. 1) or PExFDPARFLDKDGy, where x is D or N and y is L or F (SEQ ID NOs. 2 to 5).

4) Please replace the paragraph traversing pages 4 and 5 with the following:

In a further aspect, the present invention provides a peptide consisting essentially of amino acid sequence VNQWSVNHDPVKWPN (SEQ ID NO. 1) or PExFDPARFLDKDGy wherein x is D or N and y is L or F (SEQ ID NOs. 2 to 5).

5) On page 18 of the original specification, please replace Table 1 data with the following:

| | | | |
|---|--|---------|---|
| A | NLPYVLAFLYEAMRF (<u>SEQ ID NO. 6</u>) | 377-391 | - |
| B | SSFVPVTIPHATTAN (<u>SEQ ID NO. 7</u>) | 392-406 | - |
| C | TSVLGYHIPKDTVVF (<u>SEQ ID NO. 8</u>) | 407-421 | - |
| D | VNQWSVNHDVPKWPN (<u>SEQ ID NO. 1</u>) | 422-436 | + |
| E | PENFDPARFLDKDGL (<u>SEQ ID NO. 4</u>) | 437-451 | + |
| F | INKDLTSRVMIFSVG (<u>SEQ ID NO. 9</u>) | 452-466 | - |
| G | KRRCIGEELSKMQLF (<u>SEQ ID NO. 10</u>) | 467-481 | - |
| H | LFISILAHQCDFRAN (<u>SEQ ID NO. 11</u>) | 482-496 | - |
| I | PNEPAKMNFSYGLT (<u>SEQ ID NO. 12</u>) | 497-510 | - |
| J | IKPKSFKVNVTLRE (<u>SEQ ID NO. 13</u>) | 511-524 | - |

6) On page 26 of the original specification, please replace the text at lines 11 to 13 with the following:

| | |
|---------------|---|
| human CYP1B1 | PENFDPARFLDKDGL (<u>SEQ ID NO. 4</u>) |
| rat CYP1B1 | PEDFDPARFLDKDGF (<u>SEQ ID NO. 3</u>) |
| mouse CYCP1B1 | PEDFDPARFLDKDGF (<u>SEQ ID NO. 3</u>) |